Can a new lens design improve overnight vision correction?

NCT ID NCT07751172

Not yet recruiting Disease control Sponsor: CooperVision International Limited (CVIL) Source: ClinicalTrials.gov ↗

First seen Aug 07, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This trial evaluates Paragon CRT contact lenses with a 5mm optic zone diameter, worn overnight to temporarily reshape the cornea and correct myopia and astigmatism. Participants aged 6 to 35 will wear the lenses daily for a short period, and their comfort and visual performance will be assessed. The study aims to see if this lens design provides a comfortable and effective alternative to traditional glasses or daytime contacts.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Paragon CRT orthokeratology contact lenses with a 5mm optic zone diameter
What this could lead to: If successful, this could lead to more comfortable and effective overnight contact lenses for correcting nearsightedness and astigmatism.
What could go wrong: The trial is relatively small and early, and results may not apply to all lens wearers. There is also a risk of discomfort or other lens-related issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTIGMATISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

astigmatism myopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTIGMATISM MYOPIA

Contacts and locations

Locations

Bellaire Family Eye Care

Bellaire, Texas, 77401, United States
Complutense University of Madrid Av.

Madrid, Moncloa - Aravaca,, 28040, Spain
Treehouse Eyes Pleasanton Center

Pleasanton, California, 94588, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.